ROTHBLATT MARTINE A sold $5.3M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $554.61 ($548.01–$558.37, $5.27M total) across 11 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO/Chair’s same-day sale details (shares, price range, total value) and confirmation of a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for sentiment effects, but the 10b5-1 framing generally limits fundamental interpretation.
What to watch
The filing does not disclose reasons for the sale or any offsetting insider buys; without additional context, interpret cautiously.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
SEC Form 4 shows UTHR CEO/Chair Martine Rothblatt sold 9,500 shares on 2026-07-02 under a 10b5-1 plan.
Likely minimal immediate price impact; any effect would be sentiment-driven rather than fundamental.
The filing is a primary-source insider transaction with a stated 10b5-1 pre-arranged plan, reducing interpretive weight versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction; CEO/Chair Martine Rothblatt sold shares on 2026-07-02.
- insiderMartine A. Rothblatt
Chairperson & CEO who executed the open-market sale under a 10b5-1 plan.
